Evidence map›Paper›PMID 36232549›Full record

ReviewInternational journal of molecular sciences2022

Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19.

Tamanna Mustajab, Moriasi Sheba Kwamboka, Da Ae Choi, Dae Wook Kang, Junho Kim, Kyu Ri Han, Yujin Han, Sorim Lee, Dajung Song, Yong-Joon Chwae

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Extracellular Vesicles: The Invisible Heroes and Villains of COVID-19 Central Neuropathology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Tamanna MustajabDepartment of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea.ORCID 0000-0002-3259-1058
Moriasi Sheba KwambokaDepartment of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea.ORCID 0000-0002-5175-4967
Da Ae ChoiDepartment of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea.
Dae Wook KangDepartment of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea.
Junho KimDepartment of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea.
Kyu Ri HanDepartment of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea.
Yujin HanDepartment of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea.
Sorim LeeDepartment of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea.
Dajung SongDepartment of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea.
Yong-Joon ChwaeDepartment of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea.ORCID 0000-0001-7442-9457
Ajou University · KR

Funding

Ministry of Education 2019R1A6C1010003Ministry of Health and Welfare HV22C0073National Research Foundation of Korea 2022R1A2C2003413
6 · The paper itself

Abstract

The COVID-19 pandemic has had a deep impact on people worldwide since late 2019 when SARS-CoV-2 was first identified in Wuhan, China. In addition to its effect on public health, it has affected humans in various aspects of life, including social, economic, cultural, and political. It is also true that researchers have made vigorous efforts to overcome COVID-19 throughout the world, but they still have a long way to go. Accordingly, innumerable therapeutics and vaccine candidates have been studied for their efficacies and have been tried clinically in a very short span of time. For example, the versatility of extracellular vesicles, which are membrane-bound particles released from all types of cells, have recently been highlighted in terms of their effectiveness, biocompatibility, and safety in the fight against COVID-19. Thus, here, we tried to explain the use of extracellular vesicles as therapeutics and for the development of vaccines against COVID-19. Along with the mechanisms and a comprehensive background of their application in trapping the coronavirus or controlling the cytokine storm, we also discuss the obstacles to the clinical use of extracellular vesicles and how these could be resolved in the future.

Indexed as

COVID-19Extracellular VesiclesViral VaccinesCOVID-19 VaccinesHumansPandemicsSARS-CoV-2COVID-19 VaccinesViral VaccinesCOVID-19exosomesextracellular vesiclesSARS-CoV-2therapeuticsvaccine

Identifiers

PMID36232549
PMCPMC9569487
OpenAlexW4297235942

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.